Investigador Principal | Responsable del Módulo de Biopsia Líquida

Iñaki Comino-Mendez

PhD in Molecular Biosciences (Universidad Autónoma de Madrid, 2015), Hospital Universitario X

Biografía y Trayectoria

Iñaki Comino-Méndez, PhD in Molecular Biosciences (Universidad Autónoma de Madrid, 2015), is a molecular biologist with a strong background in cancer genomics and translational oncology. He is currently a Ramón y Cajal Investigator at the Instituto de Investigación Biomédica de Málaga (IBIMA) and a member of the Breast Cancer Program at CIBERONC (CB16/12/00481).

Dr. Comino-Méndez has extensive experience in liquid biopsy, including ultrasensitive detection of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) using digital PCR, targeted NGS, and fragmentomics. His research is focused on minimal residual disease (MRD) detection and relapse prediction in early breast cancer and Hodgkin lymphoma, as well as biomarker strategies in advanced tumors.

He has led over six research projects as PI, including public-private partnerships with industry. He is co-inventor of an international patent for ctDNA detection, author of more than 30 JCR-indexed publications, and has presented at international conferences such as AACR and ESMO. His work has been recognized with several awards, including the Carmen Lavigne Award (AECC, 2019–2020) and the Best Thesis in Life Sciences Award from the Royal Academy of Doctors of Spain. He actively supervises PhD and Master’s students, and his H-index is 21 (Scopus, June 2025).

Líneas de Investigación Actuales

  • Optimización de protocolos de aislamiento de ctDNA.
  • Evaluación del valor pronóstico de las Células Tumorales Circulantes (CTCs).
  • Desarrollo de paneles de secuenciación de nueva generación (NGS) adaptados a la biopsia líquida.
  • Estudio de microvesículas y exosomas en la metástasis tumoral.

Publicaciones Destacadas

Puede consultar el listado completo en el perfil ORCID.

El Dr. Toledo ha publicado más de 50 artículos en revistas peer-reviewed, incluyendo *JAMA Oncology* y *Clinical Cancer Research*. Es revisor habitual de diversas revistas científicas internacionales y participa activamente en congresos internacionales.